Nature Communications (Sep 2022)
Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
- Zhiqiang Ku,
- Xuping Xie,
- Jianqing Lin,
- Peng Gao,
- Bin Wu,
- Abbas El Sahili,
- Hang Su,
- Yang Liu,
- Xiaohua Ye,
- Eddie Yongjun Tan,
- Xin Li,
- Xuejun Fan,
- Boon Chong Goh,
- Wei Xiong,
- Hannah Boyd,
- Antonio E. Muruato,
- Hui Deng,
- Hongjie Xia,
- Jing Zou,
- Birte K. Kalveram,
- Vineet D. Menachery,
- Ningyan Zhang,
- Julien Lescar,
- Pei-Yong Shi,
- Zhiqiang An
Affiliations
- Zhiqiang Ku
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Xuping Xie
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Jianqing Lin
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Peng Gao
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Bin Wu
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Abbas El Sahili
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Hang Su
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Yang Liu
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Xiaohua Ye
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Eddie Yongjun Tan
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Xin Li
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Xuejun Fan
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Boon Chong Goh
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Wei Xiong
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Hannah Boyd
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Antonio E. Muruato
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Hui Deng
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Hongjie Xia
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Jing Zou
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Birte K. Kalveram
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Vineet D. Menachery
- Department of Microbiology & Immunology, University of Texas Medical Branch
- Ningyan Zhang
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- Julien Lescar
- NTU Institute of Structural Biology and School of Biological Sciences, Nanyang Technological University
- Pei-Yong Shi
- Department of Biochemistry and Molecular Biology, Institute for Human Infection and Immunity, Sealy Institute for Vaccine Sciences, Sealy Center for Structural Biology & Molecular Biophysics, Department of Pharmacology & Toxicology, University of Texas Medical Branch
- Zhiqiang An
- Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston
- DOI
- https://doi.org/10.1038/s41467-022-33284-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen-binding and virus neutralizing activities.
